Trimethobenzamide
- Generic Name
- Trimethobenzamide
- Brand Names
- Tigan
- Drug Type
- Small Molecule
- Chemical Formula
- C21H28N2O5
- CAS Number
- 138-56-7
- Unique Ingredient Identifier
- W2X096QY97
- Background
Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.
- Indication
For the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
- Associated Conditions
- Nausea, Nausea and vomiting
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT02373072
- Locations
- 🇺🇸
Walnut Hill Medical Center, Dallas, Texas, United States
🇺🇸Collaborative Neuroscience Network, LLC., Long Beach, California, United States
🇺🇸Parkinson's Movement Disorder Center of Maryland, Elkridge, Maryland, United States
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT02262767
- Locations
- 🇧🇪
Belgium Pfizer Clinical Research Unit, Brussels, Belgium
🇧🇪Pfizer Clinical Research Unit, Brussels, Belgium
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
- Conditions
- Motor SymptomsParkinson's DiseaseHypomobilityAkinesiaDelayed Levodopa Onset
- Interventions
- First Posted Date
- 2013-01-17
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT01770145
- Locations
- 🇺🇸
Henry Ford West Bloomfield Hospital, Bloomfield Hills, Michigan, United States
🇺🇸University of Texas Health Science Center, Houston, Department of Neurology, Houston, Texas, United States
🇺🇸Center for Neurological Care and Research, San Antonio, Texas, United States
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 117
- Registration Number
- NCT00489255
- Locations
- 🇺🇸
Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Parkinson's Disease and Movement Disorders Center of Long Island, Commack, New York, United States
🇺🇸Kingston Neurological Associates, Kingston, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.